Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
This is a phase 2 single-arm, open-label clinical trial determining efficacy of cabozantinib
in combination with pembrolizumab in subjects with advanced gastric and gastroesophageal
adenocarcinoma. These are subjects who have progressed, or not tolerated, at least one prior
line of chemotherapy with a fluoropyrimidine and platinum agent.